Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -97.64% | -90.89% | 67.44% | -91.44% | -35.78% |
| Gross Profit | 97.64% | 90.89% | -67.44% | 91.44% | 35.78% |
| SG&A Expenses | 41.40% | 135.91% | 5.73% | -14.33% | -59.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.85% | 77.79% | -57.21% | -54.34% | -51.67% |
| Operating Income | 18.85% | -77.79% | 57.21% | 54.34% | 51.67% |
| Income Before Tax | -14.05% | -30.29% | 65.61% | 44.47% | 58.18% |
| Income Tax Expenses | -- | -100.00% | 214.58% | -- | -130.00% |
| Earnings from Continuing Operations | -14.14% | -30.18% | 65.32% | 44.54% | 58.26% |
| Earnings from Discontinued Operations | -- | -- | -100.00% | -- | -236.61% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.90% | -30.18% | 65.07% | 50.93% | 54.49% |
| EBIT | 18.85% | -77.79% | 57.21% | 54.34% | 51.67% |
| EBITDA | -- | -- | 57.24% | 53.31% | 50.83% |
| EPS Basic | 90.34% | 89.68% | 95.35% | 87.02% | 69.76% |
| Normalized Basic EPS | 91.81% | 86.90% | 96.88% | 82.84% | 71.79% |
| EPS Diluted | 90.34% | 89.68% | 95.35% | 87.02% | 69.75% |
| Normalized Diluted EPS | 91.81% | 86.90% | 96.88% | 82.84% | 71.79% |
| Average Basic Shares Outstanding | 1,007.10% | 1,125.15% | 651.87% | 284.06% | 50.59% |
| Average Diluted Shares Outstanding | 1,007.10% | 1,125.15% | 651.87% | 284.06% | 50.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |